Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marcos Rezende Teixeira"'
Autor:
L.B. Mendes Gomes, Daniel Garcia, Monique Celeste Tavares, Marcel Vieira Barreto Silva, José Augusto Rinck, J.P.S. Lima, C.D. De Liz, Thiago Bueno Oliveira, Marcos Rezende Teixeira
Publikováno v:
Annals of Oncology. 32:S883
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c63a8aee4923ba4c1ef1b91d1285860
https://doi.org/10.1016/j.annonc.2021.08.1444
https://doi.org/10.1016/j.annonc.2021.08.1444
Autor:
Monique Celeste Tavares, Marcos Rezende Teixeira, João Pedreira Duprat, Daniel Garcia, Joao Lima, Thiago Bueno Oliveira, Marcelo Cavicchioli, Caio Dabbous Liz, Eduardo Lima, José Augusto Rinck, Luciana Beatriz Mendes Gomes Siqueira, Milton Jose De Barros E. Silva
Publikováno v:
Journal of Clinical Oncology. 39:e21533-e21533
e21533 Background: Combination therapy with anti-PD1 and low-dose ipilimumab has shown reduced rate of immune-related adverse effects compared with standard dose used in the Checkmates studies 067 and 204. However, the discussion whether low-dose ipi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86e68470420f62bae938099a9a006149
https://doi.org/10.1200/jco.2021.39.15_suppl.e21533
https://doi.org/10.1200/jco.2021.39.15_suppl.e21533
Autor:
José Augusto Rinck, Daniel Garcia, Matheus de Melo Lôbo, Marcelo Cavicchioli, Marcos Rezende Teixeira, Eduardo Bertolli, João Pedreira Duprat, Kenneth J. Gollob, Clovis Antonio Lopes Pinto, Caio Dabbous Liz, André Sapata Molina, Joao Lima, Eduardo Lima, Amanda B. Figueiredo, Monique Celeste Tavares, Milton Jose De Barros E. Silva
Publikováno v:
Journal of Clinical Oncology. 39:e21569-e21569
e21569 Background: Neoadjuvant immunotherapy with nivolumab 3mg/kg and ipilimumab 1mg/kg for two cycles(N3+I1) or anti-PD1 for 3-8 weeks for clinical stage III melanoma have shown rates of pCR/near-pCR about 60% or 30%, respectively. The prognosis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc0285f067003e401e073eb20a4f32dd
https://doi.org/10.1200/jco.2021.39.15_suppl.e21569
https://doi.org/10.1200/jco.2021.39.15_suppl.e21569
Autor:
Daniel Garcia, Monique Celeste Tavares, João Pedreira Duprat, José Augusto Rinck, Marcos Rezende Teixeira, Thiago Bueno Oliveira, Natasha Carvalho Pandolfi, Milton Jos De Barros E Silva, Joao Paulo Sn Lima, Vinicius Fernando Calsavara
Publikováno v:
Journal of Clinical Oncology. 38:e22045-e22045
e22045 Background: Immune checkpoint blockade (ICB) has changed the natural history advanced melanoma (AM) with response rates about 40% and overall survival in 5 years of more than 30%. Interestingly, the site of metastasis may have impact on immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::185d9df660640fd1da42a0a4d98c0917
https://doi.org/10.1200/jco.2020.38.15_suppl.e22045
https://doi.org/10.1200/jco.2020.38.15_suppl.e22045
Autor:
Monique Celeste Tavares, Milton Jos De Barros E Silva, Vinicius Fernando Calsavara, José Augusto Rinck, Daniel Garcia, João Pedreira Duprat, Natasha Carvalho Pandolfi, Marcos Rezende Teixeira, Joao Paulo Sn Lima, Thiago Bueno Oliveira
Publikováno v:
Journal of Clinical Oncology. 38:10046-10046
10046 Background: Immune checkpoint blockade (ICB) has changed the natural history advanced melanoma (AM). Based on phase III trial, which used RECIST criteria, the complete response (CR) rate with anti-PD1 therapy is around 20%. In daily practice, P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5774a73de378e2d455efee540887ff3
https://doi.org/10.1200/jco.2020.38.15_suppl.10046
https://doi.org/10.1200/jco.2020.38.15_suppl.10046